HAVN Life Sciences Inc
HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psil… Read more
HAVN Life Sciences Inc (HAVLF) - Total Liabilities
Latest total liabilities as of January 2023: $540.44K USD
Based on the latest financial reports, HAVN Life Sciences Inc (HAVLF) has total liabilities worth $540.44K USD as of January 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
HAVN Life Sciences Inc - Total Liabilities Trend (2020–2022)
This chart illustrates how HAVN Life Sciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
HAVN Life Sciences Inc Competitors by Total Liabilities
The table below lists competitors of HAVN Life Sciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TULLOW OIL (TQW.SG)
STU:TQW
|
Germany | €4.82 Billion |
|
CARAVEL MIN
BE:STC
|
Germany | €1.09 Million |
|
SysGroup PLC
LSE:SYS
|
UK | GBX13.52 Million |
|
Namliong SkyCosmos Inc
PINK:NLSC
|
USA | $1.94 Million |
Liability Composition Analysis (2020–2022)
This chart breaks down HAVN Life Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HAVN Life Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HAVN Life Sciences Inc (2020–2022)
The table below shows the annual total liabilities of HAVN Life Sciences Inc from 2020 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-04-30 | $918.46K | -11.72% |
| 2021-04-30 | $1.04 Million | +2430.76% |
| 2020-04-30 | $41.11K | -- |